Mybacs has set itself the goal of revolutionizing the health market surrounding the human microbiome. The company, based in Munich and Zug, Switzerland, focuses on synbiotic dietary supplements, which are tailored to the individual needs and areas of application of its customers through their formulation of specifically selected bacterial cultures, prebiotics, minerals, and vitamins.
The young company has been on the market since 2018. Following a successful first round of financing in August 2019, the second round now follows. Mybacs has once again impressed existing investors such as the VC fund Global Founders Capital. New investors such as Joyance Partners are also participating in this round. The total investment amount was not disclosed. The new capital will primarily be used to expand the team and develop a tech platform to further advance product personalization.
“Great demand for products related to intestinal health”
“We are very pleased about the new financing round and the trust our investors have placed in us,”
says Carl Philipp von Polheim, founder and co-CEO of Mybacs. He continues:
"The positive response from our customers and the associated growth since the launch of our Dailybacs once again confirms the great demand for products related to intestinal health and the human microbiome. This is precisely where we want to continue with the new investment and focus on developing additional products to be able to respond even more specifically to the individual needs of our customers. Accordingly, we will expand the team with specialists in the technology and data sectors and further advance the personalization of our products with the help of a platform for symptomatic and intelligent data analysis."
The daily dose of synbiotic
Mybacs has been on the market since 2018 with its travel product 'Travelbacs' – a regionally tailored bacterial composition to prepare the digestive system for specific travel destinations. In 2019, the startup expanded its product portfolio to include 'Dailybacs', a subscription-based synbiotic for daily use, specifically tailored to the needs of women, men, and children.
